BMY.N
現在値
65.63USD変化
0.46(+0.71%)出来高
2,934,772本日のレンジ
-
65.8752週レンジ
-
68.34∙ 約20分前の相場を表示しています。
Feb 13 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS FOR PRIORITY REVIEW BRISTOL-MYERS SQUIBB’S BIOLOGICS LICENSE APPLICATION (BLA) FOR LISOCABTAGENE MARALEUCEL (LISO-CEL) FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA.BRISTOL-MYERS SQUIBB CO - FDA HAS SET A PDUFA GOAL DATE OF AUGUST 17, 2020.
Feb 4 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BIOMOTIV AND BRISTOL-MYERS SQUIBB ANNOUNCE THE LAUNCH OF ANTEROS PHARMACEUTICALS.BRISTOL-MYERS SQUIBB - UNDER TERMS OF PARTNERSHIP, CO WILL CONTRIBUTE IP, DATA, REAGENTS FOR SERIES OF SMALL MOLECULES AGAINST UNDISCLOSED MECHANISM.BRISTOL-MYERS SQUIBB CO - ONCE ANTEROS NOMINATES PRE-CLINICAL CANDIDATE, CO HAS OPTION TO ACQUIRE ANTEROS FROM BIOMOTIV UNDER PRE-AGREED TERMS.
Jan 31 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB WITHDRAWS EUROPEAN APPLICATION OF OPDIVO PLUS YERVOY FOR FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER.BRISTOL-MYERS - HAS NO PLANS TO REFILE APPLICATION OF OPDIVO PLUS YERVOY FOR FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER IN EU.BRISTOL-MYERS - U.S. APPLICATION FOR OPDIVO & YERVOY IN FIRST-LINE NSCLC BASED ON CHECKMATE -227 STUDY UNDER REVIEW WITH PDUFA DATE OF MAY 15.
Jan 15 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS FOR PRIORITY REVIEW BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN FIRST-LINE NON-SMALL CELL LUNG CANCER.BRISTOL-MYERS SQUIBB CO - FDA HAS GRANTED APPLICATION PRIORITY REVIEW WITH A PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF MAY 15, 2020.
Jan 10 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::NEKTAR THERAPEUTICS AND BRISTOL-MYERS SQUIBB AMEND STRATEGIC COLLABORATION AGREEMENT FOR BEMPEGALDESLEUKIN PLUS OPDIVO (NIVOLUMAB).NEKTAR THERAPEUTICS - COSTS FOR STUDIES WILL BE SHARED BASED UPON COST-SHARING OUTLINED IN TERMS OF ORIGINAL COLLABORATION AGREEMENT.NEKTAR THERAPEUTICS - CO, BRISTOL AGREED TO NEW JOINT DEVELOPMENT PLAN TO ADVANCE BEMPEGALDESLEUKIN PLUS OPDIVO INTO MULTIPLE NEW REGISTRATIONAL TRIALS.NEKTAR THERAPEUTICS - BRISTOL-MYERS TO INDEPENDENTLY CONDUCT PHASE 1/2 DOSE STUDY IN FIRST-LINE NON-SMALL-CELL LUNG CANCER WITH BEMPEG AND NIVOLUMAB.NEKTAR THERAPEUTICS- PHASE 1/2 DOSE ESCALATION, EXPANSION STUDY TO BE INITIATED TO EVALUATE BEMPEG PLUS NIVOLUMAB IN COMBINATION WITH AXITINIB IN FIRST-LINE RCC.NEKTAR THERAPEUTICS - CO, BRISTOL TO EXPAND DEVELOPMENT PROGRAM FOR BEMPEG PLUS NIVOLUMAB TO INCLUDE 2 ADDITIONAL REGISTRATIONAL TRIALS.
Dec 23 (Reuters) - U.S. FDA::U.S. FDA - APPROVES FIRST GENERICS OF ELIQUIS.FDA - APPROVED 2 APPLICATIONS FOR GENERICS OF ELIQUIS TABLETS TO LOWER RISK OF STROKE, SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.FDA - GRANTED APPROVAL OF GENERIC APIXABAN APPLICATIONS TO MICRO LABS LIMITED & MYLAN PHARMACEUTICALS.
Dec 18 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR CAR T-CELL THERAPY LISOCABTAGENE MARALEUCEL (LISO-CEL) TO FDA.BRISTOL-MYERS SQUIBB - BLA SUBMISSION LISOCABTAGENE MARALEUCEL (LISO-CEL) IS BASED ON SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001 TRIAL.
Dec 13 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB ANNOUNCES LEADERSHIP CHANGES.BRISTOL-MYERS SQUIBB CO - JOHN ELICKER TO RETIRE IN MARCH 2020.BRISTOL-MYERS SQUIBB CO - KATHRYN METCALFE APPOINTED EXECUTIVE VICE PRESIDENT, CORPORATE AFFAIRS.BRISTOL-MYERS SQUIBB - TIM POWER HAS BEEN APPOINTED VICE PRESIDENT AND HEAD OF INVESTOR RELATIONS, EFFECTIVE MARCH 31, 2020 UPON ELICKER'S RETIREMENT.
Dec 10 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB PRESENTS OVERALL SURVIVAL AND SAFETY DATA FROM PIVOTAL CC-486 STUDY QUAZAR AML-001.BRISTOL-MYERS SQUIBB CO - CC-486 HAD A MANAGEABLE SAFETY PROFILE.BRISTOL-MYERS - MAINTENANCE TREATMENT WITH CC-486 RESULTED IN SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL VERSUS PLACEBO FOR FRONT-LINE AML PATIENTS.BRISTOL-MYERS - TREATMENT WITH CC-486 IN MAINTENANCE SETTING PROVIDED PATIENTS A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS.BRISTOL-MYERS - AT MEDIAN FOLLOW-UP OF 41.2 MONTHS, PRIMARY ENDPOINT OF OS SIGNIFICANTLY IMPROVED FOR PATIENTS RECEIVING CC-486 COMPARED TO PLACEBO.BRISTOL-MYERS SQUIBB CO - BASED ON RESULTS OF QUAZAR AML-001, BRISTOL-MYERS SQUIBB IS PLANNING REGULATORY SUBMISSIONS IN FIRST HALF OF 2020.
Dec 9 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::REBLOZYL® (LUSPATERCEPT-AAMT) STUDIES EVALUATING TREATMENT OF ANEMIA IN RARE BLOOD DISEASES PRESENTED AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING.BRISTOL-MYERS SQUIBB CO - CO, ACCELERON PLAN TO INITIATE PIVOTAL, PHASE 3 STUDY CALLED INDEPENDENCE IN 2020.BRISTOL-MYERS- LONGER-TERM FOLLOW-UP FROM PHASE 3 STUDIES OF MEDALIST IN MDS-ASSOCIATED ANEMIA SHOWED PATIENTS EXPERIENCING SUSTAINED CLINICAL BENEFIT.BRISTOL-MYERS- FOLLOW-UP FROM PHASE 3 STUDIES OF MEDALIST IN BELIEVE IN BETA THALASSEMIA-ASSOCIATED ANEMIA ALSO SHOWED SUSTAINED CLINICAL BENEFIT.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。